According to eHealth's report on May 15th, the latest court ruling allows Nicotine Replacement Therapy (NRT) to be sold in retail stores, expanding the availability of this breakthrough treatment. This milestone decision highlights the effectiveness of NRT in aiding individuals in the process of quitting smoking, and its prominent position on the national essential medicines list since 2022. This legal recognition further strengthens its core role in public health programs aimed at controlling tobacco use.
Prominent experts in the medical field have praised this ruling, calling it a significant advancement. Dr. Chandrakant S Pandav, former head of the Community Medicine Department at the All India Institute of Medical Sciences (AIIMS) and recipient of the Lotus Award, commended the decision, emphasizing the importance of NRT in providing essential support for smokers looking to quit.
He stated, "This decision marks a significant shift in the concept of nicotine replacement therapy (NRT). For smokers looking to quit, NRT is a safe and effective tool, and this ruling rightfully acknowledges that fact. NRT plays a crucial role in providing necessary support for smokers to gradually reduce nicotine intake and achieve a smoke-free life, which is a goal that many smokers aspire to reach. The recent lifting of the ban and increased accessibility will have a positive impact on smoking cessation.
A recent court ruling marks a significant shift in historical viewpoints, as NRT has now been removed from the 1919 Poisons Act, signaling a change in direction for smoking cessation strategies. By acknowledging the value of NRT and making it more widely available, this decision has the potential to save countless lives and create a healthier society.
Dr. Niranjan Naik, head of oncological surgery at the Indian Fortis Memorial Research Institute (FMRI), has emphasized the transformative potential of increasing the accessibility of Nicotine Replacement Therapy (NRT). He stated, "This decision is a game-changer, as it paves the way for making NRT more widespread. NRT is a safe and effective tool, widely recognized as the most effective form of smoking cessation aid. By allowing for its wider availability, we can empower millions of smokers who truly want to quit but struggle with withdrawal symptoms. Enhancing the accessibility of NRT can greatly improve public health outcomes and bring a healthier future for our communities. Availability in retail stores will help people on their path to quitting smoking.
According to data from the World Health Organization (WHO), over one million people die each year in India alone due to smoking. However, Nicotine Replacement Therapy (NRT) is providing a glimmer of hope in the battle against tobacco addiction. NRT offers controlled doses of nicotine in various forms such as gum, patches, inhalers, and lozenges to help curb cravings and make the transition to a smoke-free life easier. Progress towards wider availability of NRT could lead to significant advancements in anti-smoking efforts, ultimately leading to a healthier, smoke-free India.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
